NASH Updates: Intercept Moves Toward Re-Filing, Madrigal De-Risks Phase III

 
• By Joseph Haas
  
Liver disease
Intercept, Madrigal, Akero, 89Bio update their progress at AASLD
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D